This biotechnology company provides adaptive and scalable simulations of human physiology to accelerate drug discovery. Their platform helps research institutes improve the efficiency of drug development by offering accurate insights into drug performance.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional in vitro models often fail to accurately replicate the complex physiological conditions of human infections, leading to inaccurate results in drug development and treatment selection. Animal models, while more complex, are expensive, ethically questionable, and may not precisely mimic human physiology. This lack of accurate models hinders the development of effective treatments, especially for chronic infections and antibiotic resistance.
Solution
SynthBiome designs and manufactures synthetic biological models that mimic the physiological conditions microorganisms encounter in specific human infection environments. Using a quantitative framework based on gene expression, SynthBiome creates accurate synthetic media that closely replicate the infection site environment, ensuring that pathogens exhibit behaviors similar to those observed in vivo. This approach enables more effective drug development and treatment selection by providing researchers with a controlled and reproducible environment that closely mirrors the complexities of human infections. SynthBiome offers both pre-designed models, such as those for cystic fibrosis and chronic wound infections, and custom-designed models tailored to specific research needs.
Target Audience
The primary target audience includes researchers in pharmaceutical companies, research institutes, and academic labs focused on drug development, treatment selection, and host-pathogen interactions, particularly in the areas of cystic fibrosis, chronic wound infections, and antibiotic resistance.
Features
- Synthetic growth media designed to mimic specific human infection environments, including CF-sputum and chronic wound environments.
- Quantitative framework using gene expression data to ensure accurate replication of in vivo physiological conditions.
- Pre-designed models available for cystic fibrosis research (SCFM1 and SCFM2) and chronic wound infection research (LCWB).
- Custom model design and development services to meet specific research goals.
- Accuracy Score (AS2) benchmarking for SCFMs, measured for the Pseudomonas aeruginosa CF-lung core genome.
- Quality control testing to ensure adequate growth of relevant bacterial species in each model.